Expand all sections

Trastuzumab deruxtecan

Enhertu

Extended indication

Extension of indication to include monotherapy treatment of adult patients with locally advanced or

Therapeutic value

No estimate possible yet
Registration phase

Registration application pending

Product

Active substance

Trastuzumab deruxtecan
Domain

Oncology and Hematology
Reason of inclusion

Indication extension
Main indication

Stomach cancer
Extended indication

Extension of indication to include monotherapy treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior anti-HER2-based regimen
Proprietary name

Enhertu
Manufacturer

AstraZeneca
Mechanism of action

Antibody-drug conjugate
Route of administration

Intravenous
Therapeutical formulation

Injection / infusion solution
Budgetting framework

Intermural (MSZ)

Registration

Registration route

Centralised (EMA)
Type of trajectory

Normal trajectory
ATMP

No
Submission date

October 2021
Expected Registration

August 2022
Orphan drug

No
Registration phase

Registration application pending
Additional comments 
De fabrikant verwacht registratie in de tweede helft van 2022.

Therapeutic value

Therapeutic value

No estimate possible yet
Substantiation

Op dit moment loopt de DESTINY-Gastric02 studie nog.
Frequency of administration

1 times every 3 weeks
Dosage per administration

6,4mg/kg

Expected patient volume per year

Patient volume

< 78

Market share is generally not included unless otherwise stated.
References 
IKNL; expertopinie; Record rivoceranib
Additional comments 
Ongeveer 70 patiënten worden behandeld in de tweede lijn voor gemetastaseerd adenocarcinoom van de maag of gastro-oesofageale overgang. Het aantal patiënten met een slokdarmcarcinoom die in de tweede lijn worden behandeld bedraagt ongeveer 60. In totaal zijn dit dus 130 patiënten. De inschatting is dat hiervan maximaal 60% een derdelijns behandeling krijgt (78 patiënten).

Expected cost per patient per year

References 
https://www.fiercepharma.com/special-report/1-enhertu
Additional comments 
Op basis van de Amerikaanse verwachte prijs: $13,300 per maand.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

Indication extension

Yes
Indication extensions

Treatment of adult patients with unresectable or metastatic HER2 positive breast cancer who have received two or more prior anti HER2 based regimens (NCT03248492). Treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2 therapies (2L) (NCT03529110). Treatment of adult patients with unresectable or metastatic HER2-Low breast cancer. Treatment of adult patients with HER2-mutated, Unresectable and/or Metastatic non-small cell lung cancer (NSCLC) (NCT03505710).

Other information

There is currently no futher information available.